25 research outputs found
Low nasal carriage of drug-resistant bacteria among medical students in Vienna
Background: Multi-drug resistant bacteria are increasing and remain a major public health challenge worldwide. In order to understand the potential role of medical students as a reservoir for circulating pathogenic bacteria and their transmission, we analysed the nasal colonisation among 86 clinically exposed medical students of the Medical University of Vienna, which is integrated into General Hospital of Vienna
Schistosomiasis in European Travelers and Migrants: Analysis of 14 Years TropNet Surveillance Data
Schistosomiasis; Travelers and migrants; EuropeEsquistosomosi; Viatgers i migrants; EuropaEsquistosomiasis; Viajeros y migrantes; EuropaSchistosomiasis remains one of the most prevalent parasitic diseases worldwide and the infection is frequently found in travelers and migrants. The European Network for Tropical Medicine and Travel Health conducted a sentinel surveillance study on imported schistosomiasis between 1997 and 2010. This report summarizes epidemiological and clinical data from 1,465 cases of imported schistosomiasis. Direct pathogen detection and serology were the main diagnostic tools applied. Of these, 486 (33%) cases were identified among European travelers, 231 (16%) among long-term expatriates, and 748 (51%) among non-European immigrants. Overall, only 18.6% of travelers had received pretravel advice; 95% of infections were acquired in the African region. On species level, Schistosoma mansoni was identified in 570 (39%) and Schistosoma haematobium in 318 (22%) cases; 57.5% of patients were symptomatic. Acute symptoms were reported in 27% of patients leading to earlier presentation within 3 months. Praziquantel was used in all patients to treat schistosomiasis. Many infections were detected in asymptomatic patients. In 47.4% of asymptomatic patients infection was detected by microscopy and in 39% by serology or antigen testing. Schistosomiasis remains a frequent infection in travelers and migrants to Europe. Travelers should be made aware of the risk of schistosomiasis infection when traveling to sub-Saharan Africa. Posttravel consultations particularly for returning expatriates are useful given the high potential for detecting asymptomatic infections
In vitro activity of immunosuppressive drugs against Plasmodium falciparum
Background Solid organ transplant recipients are particularly vulnerable for
infectious diseases due to prolonged immunosuppressive treatment. Residents of
endemic regions and travellers may be exposed to malaria and may, therefore,
require prolonged antimalarial chemoprophylaxis. The hypothesis of this study
was that certain immunosuppressive drugs may exert clinically relevant anti-
malarial activity. It was therefore designed to assess the intrinsic anti-
malarial activity of everolimus, mycophenolic acid, and rapamycin against
Plasmodium falciparum in an in vitro model. Methods Three laboratory adapted
clones of P. falciparum and two isolates were used to assess the potential of
mycophenolic acid, rapamycin and everolimus to inhibit in vitro growth of P.
falciparum. The standard histidine rich protein 2 assay was employed and
inhibitory drug concentrations (IC) were computed by non-linear regression
analysis. Results All drugs were associated with complete inhibition of P.
falciparum growth in in vitro assays. Mycophenolic acid demonstrated IC50 and
IC90 values of 5.4 μmol/L and 15.3 μmol/L. Rapamycin inhibited P. falciparum
growth at 7.2 μmol/L (IC50) and 12.5 μmol/L (IC90), respectively. Finally,
everolimus displayed IC50 and IC90 values of 6.2 μmol/L and 11.5 μmol/L. There
was no difference in in vitro activity against chloroquine sensitive or
chloroquine resistant parasites. Conclusions All immunosuppressive drugs
evaluated in this in vitro study demonstrated activity against P. falciparum.
Inhibitory concentrations of mycophenolic acid are within clinically
achievable plasma concentrations when used in solid organ transplant
recipients. Further in vivo evaluation of mycophenolic acid either alone or in
combination regimens may prove promising for the concomitant prevention of P.
falciparum in solid organ transplant recipients living or travelling in
malaria endemic regions
Azithromycin inhibits IL-1 secretion and non-canonical inflammasome activation
Deregulation of inflammasome activation was recently identified to be involved
in the pathogenesis of various inflammatory diseases. Although macrolide
antibiotics display well described immunomodulatory properties, presumably
involved in their clinical effects, their impact on inflammasome activation
has not been investigated. We compared the influence of macrolides on cytokine
induction in human monocytes. The role of intracellular azithromycin-
accumulation was examined by interference with Ca++-dependent uptake. We have
also analysed the signalling cascades involved in inflammasome activation, and
substantiated the findings in a murine sepsis model. Azithromycin, but not
clarithromycin or roxithromycin, specifically inhibited IL-1α and IL-1β
secretion upon LPS stimulation. Interference with Ca++-dependent uptake
abolished the cytokine-modulatory effect, suggesting a role of intracellular
azithromycin accumulation in the modulatory role of this macrolide.
Azithromycin’s inhibiting effects were observed upon LPS, but not upon
flagellin, stimulation. Consistent with this observation, we found impaired
induction of the LPS-sensing caspase-4 whereas NF-κB signalling was
unaffected. Furthermore, azithromycin specifically affected IL-1β levels in a
murine endotoxin sepsis model. We provide the first evidence of a differential
impact of macrolides on the inflammasome/IL-1β axis, which may be of relevance
in inflammasome-driven diseases such as chronic obstructive pulmonary disease
or asthma
Initial Experience With SARS-CoV-2-Neutralizing Monoclonal Antibodies in Kidney or Combined Kidney-Pancreas Transplant Recipients
Background: Antiviral drugs have shown little impact in patient infected with acute respiratory coronavirus 2 (SARS-CoV-2). Especially for immunocompromised persons positive for SARS-CoV-2, novel treatments are warranted. Recently, the U.S. FDA has granted an emergency use authorization (EUA) to two monoclonal antibodies (mAb) targeting the viral spike protein: bamlanivimab and casivirimab and imdevimab. As per the EUA, all SARS-CoV-2 positive organ transplant recipients can receive mAb treatment.
Patients and methods: We queried our center's transplant registry to identify SARS-CoV-2 infected recipients treated with single doses of either Bamlanivimab or casivirimab/imdevimab up to May 31, 2021. We analyzed clinical outcomes, renal function and virus-specific antibodies. The co-primary endpoints were hospitalization due to COVID-19 and SARS-CoV-2 RT-PCR negativity.
Results: Thirteen patients at a median interval of 55 (IQR, 26-110) months from transplant were treated: 8 with bamlanivimab and 5 with casivirimab/imdevimab. In all, 4/13 (31%) patients were hospitalized at some time, while 11/13 (85%) achieved PCR negativity. 2/4 hospitalized patients received mAb as rescue treatment. Overall mortality was 23%, with one death attributable to transplant-associated lymphoma. All six patients infected with the B 1.1.7 variant were alive at last contact.
Conclusion: mAb treatment appears effective when administered early to SARS-CoV-2-infected transplant recipients
Schistosomiasis in european travelers and migrants: Analysis of 14 years tropnet surveillance data
Hemolysis after Oral Artemisinin Combination Therapy for Uncomplicated Plasmodium falciparum
A time-resolved proteomic and prognostic map of COVID-19.
COVID-19 is highly variable in its clinical presentation, ranging from asymptomatic infection to severe organ damage and death. We characterized the time-dependent progression of the disease in 139 COVID-19 inpatients by measuring 86 accredited diagnostic parameters, such as blood cell counts and enzyme activities, as well as untargeted plasma proteomes at 687 sampling points. We report an initial spike in a systemic inflammatory response, which is gradually alleviated and followed by a protein signature indicative of tissue repair, metabolic reconstitution, and immunomodulation. We identify prognostic marker signatures for devising risk-adapted treatment strategies and use machine learning to classify therapeutic needs. We show that the machine learning models based on the proteome are transferable to an independent cohort. Our study presents a map linking routinely used clinical diagnostic parameters to plasma proteomes and their dynamics in an infectious disease
Recommended from our members
Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study.
Funder: Humboldt-Universität zu Berlin (1034)PURPOSE: Adequate patient allocation is pivotal for optimal resource management in strained healthcare systems, and requires detailed knowledge of clinical and virological disease trajectories. The purpose of this work was to identify risk factors associated with need for invasive mechanical ventilation (IMV), to analyse viral kinetics in patients with and without IMV and to provide a comprehensive description of clinical course. METHODS: A cohort of 168 hospitalised adult COVID-19 patients enrolled in a prospective observational study at a large European tertiary care centre was analysed. RESULTS: Forty-four per cent (71/161) of patients required invasive mechanical ventilation (IMV). Shorter duration of symptoms before admission (aOR 1.22 per day less, 95% CI 1.10-1.37, p < 0.01) and history of hypertension (aOR 5.55, 95% CI 2.00-16.82, p < 0.01) were associated with need for IMV. Patients on IMV had higher maximal concentrations, slower decline rates, and longer shedding of SARS-CoV-2 than non-IMV patients (33 days, IQR 26-46.75, vs 18 days, IQR 16-46.75, respectively, p < 0.01). Median duration of hospitalisation was 9 days (IQR 6-15.5) for non-IMV and 49.5 days (IQR 36.8-82.5) for IMV patients. CONCLUSIONS: Our results indicate a short duration of symptoms before admission as a risk factor for severe disease that merits further investigation and different viral load kinetics in severely affected patients. Median duration of hospitalisation of IMV patients was longer than described for acute respiratory distress syndrome unrelated to COVID-19
Severe malaria in Europe: an 8-year multi-centre observational study
Background: Malaria remains one of the most serious infections for travellers to tropical countries. Due to the lack of harmonized guidelines a large variety of treatment regimens is used in Europe to treat severe malaria. Methods: The European Network for Tropical Medicine and Travel Health (TropNet) conducted an 8-year, multicentre, observational study to analyse epidemiology, treatment practices and outcomes of severe malaria in its member sites across Europe. Physicians at participating TropNet centres were asked to report pseudonymized retrospective data from all patients treated at their centre for microscopically confirmed severe Plasmodium falciparum malaria according to the 2006 WHO criteria. Results: From 2006 to 2014 a total of 185 patients with severe malaria treated in 12 European countries were included. Three patients died, resulting in a 28-day survival rate of 98.4%. The majority of infections were acquired in West Africa (109/185, 59%). The proportion of patients treated with intravenous artesunate increased from 27% in 2006 to 60% in 2013. Altogether, 56 different combinations of intravenous and oral drugs were used across 28 study centres. The risk of acute renal failure (36 vs 17% p = 0.04) or cerebral malaria (54 vs 20%, p = 0.001) was significantly higher in patients ≥60 years than in younger patients. Respiratory distress with the need for mechanical ventilation was significantly associated with the risk of death in the study population (13 vs 0%, p = 0.001). Post-artemisinin delayed haemolysis was reported in 19/70 (27%) patients treated with intravenous artesunate. Conclusion: The majority of patients with severe malaria in this study were tourists or migrants acquiring the infection in West Africa. Intravenous artesunate is increasingly used for treatment of severe malaria in many European treatment centres and can be given safely to European patients with severe malaria. Patients treated with intravenous artesunate should be followed up to detect and manage late haemolytic events